Document Detail

Usefulness of Beta-Blocker Therapy and Outcomes in Patients With Pulmonary Arterial Hypertension.
MedLine Citation:
PMID:  22385756     Owner:  NLM     Status:  Publisher    
Pulmonary arterial hypertension (PAH) is a disorder in which pulmonary arterial remodeling and vasoconstriction progressively lead to right heart failure (HF), exercise intolerance, and high mortality. Beta-blockers have been shown to decrease mortality in left-sided HF, but their efficacy in isolated right HF associated with PAH is uncertain. Patients with PAH may have cardiac co-morbidities for which β-blocker therapy is indicated, and the relative risk benefit of this therapy remains to be proved. This is a prospective cohort study of 94 consecutive patients with PAH divided into 2 groups with and without β-blocker use at baseline. Rate of all-cause mortality, PAH-related hospitalization, change in 6-minute walk test, right ventricular structure and function measured by echocardiography, and hemodynamics measured by right heart catheterization were determined between subjects with and without β-blocker use. Beta-blocker use was common (28%) in this cohort. After a median follow-up of 20 months, changes in pulmonary hemodynamics and right ventricular size and function were similar between groups. There were no statistically significant differences in adverse events including PAH-related hospitalization or all-cause mortality (p = 0.19), presence of right HF by last visit (p = 0.75), or change in last 6-minute walk distance (p = 0.92). In conclusion, β-blocker use is not uncommon in a select group of patients with PAH and cardiac co-morbidities and did not appear to exert detrimental effects in clinical, functional, and hemodynamic outcomes. Further randomized data are needed to evaluate the potential benefits and risks of β-blocker use in patients with PAH.
Petsy Pui-Sze So; Ross A Davies; George Chandy; Duncan Stewart; Rob S B Beanlands; Haissam Haddad; Carolyn Pugliese; Lisa M Mielniczuk
Related Documents :
11479476 - The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic paramet...
12587806 - Angiotensin ii receptor blockers in heart failure.
7818836 - Socioeconomic aspects of ace inhibition in the secondary prevention in cardiovascular d...
18312906 - Traditional and novel approaches to management of heart failure: successes and failures.
832356 - Xxii. intractable paroxysmal tachycardias which proved fatal in type a wolff-parkinson-...
8237836 - Canadian amiodarone myocardial infarction arrhythmia trial (camiat): rationale and prot...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-29
Journal Detail:
Title:  The American journal of cardiology     Volume:  -     ISSN:  1879-1913     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-3-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of air gun noise on the behaviour of marine fish and squid.
Next Document:  [Effect of photocoagulation on center point thickness in diabetic macular edema].